SEC··Finance
SEC Form 6-K filed by HSBC Holdings plc.
6-K - HSBC HOLDINGS PLC (0001089113) (Filer)
Insights
Search across every press release, SEC filing, FDA approval, analyst rating, and insider trade. Filter by company, sector, source, category, or date range.
25+ resultsLive feed →
SEC Form 6-K filed by HSBC Holdings plc. SEC Form 8-K filed by Enanta Pharmaceuticals Inc. SEC··Health CareSEC Form 8-K filed by Enanta Pharmaceuticals Inc.
8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
Roth Capital initiated coverage on Anfield Energy with a new price target ANALYST··Basic MaterialsRoth Capital initiated coverage on Anfield Energy with a new price target
Roth Capital initiated coverage of Anfield Energy with a rating of Buy and set a new price target of $5.00
Manulife Financial downgraded by Scotiabank ANALYST··FinanceManulife Financial downgraded by Scotiabank
Scotiabank downgraded Manulife Financial from Sector Outperform to Sector Perform
SEC Form 8-K filed by Flex Ltd. SEC Form 8-K filed by Blackbaud Inc. SEC Form 8-K filed by Etsy Inc. SEC Form 8-K filed by Littelfuse Inc. SEC Form 425 filed by Range Resources Corporation SEC··EnergySEC Form 425 filed by Range Resources Corporation
425 - RANGE RESOURCES CORP (0000315852) (Subject)
SEC Form 8-K filed by Replimune Group Inc. SEC··Health CareSEC Form 8-K filed by Replimune Group Inc.
8-K - Replimune Group, Inc. (0001737953) (Filer)
SEC Form 10-Q filed by Hayward Holdings Inc. SEC··IndustrialsSEC Form 10-Q filed by Hayward Holdings Inc.
10-Q - Hayward Holdings, Inc. (0001834622) (Filer)
SEC Form 10-Q filed by Amarin Corporation plc SEC··Health CareSEC Form 10-Q filed by Amarin Corporation plc
10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
SEC Form 8-K filed by Amarin Corporation plc SEC··Health CareSEC Form 8-K filed by Amarin Corporation plc
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
SEC Form 8-K filed by Terex Corporation SEC Form 8-K filed by Axogen Inc. SEC Form 8-K filed by D-Wave Quantum Inc. SEC··TechnologySEC Form 8-K filed by D-Wave Quantum Inc.
8-K - D-Wave Quantum Inc. (0001907982) (Filer)
SEC Form 6-K filed by Oatly Group AB SEC··Consumer StaplesSEC Form 6-K filed by Oatly Group AB
6-K - Oatly Group AB (0001843586) (Filer)
SEC Form 8-K filed by Hayward Holdings Inc. SEC··IndustrialsSEC Form 8-K filed by Hayward Holdings Inc.
8-K - Hayward Holdings, Inc. (0001834622) (Filer)
SEC Form 10-Q filed by Masco Corporation SEC··IndustrialsSEC Form 10-Q filed by Masco Corporation
10-Q - MASCO CORP /DE/ (0000062996) (Filer)
SEC Form 8-K filed by Bausch + Lomb Corporation SEC··Health CareSEC Form 8-K filed by Bausch + Lomb Corporation
8-K - Bausch & Lomb Corp (0001860742) (Filer)
FLEX REPORTS SECOND QUARTER FISCAL 2027 RESULTS PR··TechnologyFLEX REPORTS SECOND QUARTER FISCAL 2027 RESULTS
Reported Q2 net sales of $8.5 billion, up 25% versus the prior year. Delivered Q2 GAAP operating margin of 4.9%, and adjusted operating margin of 7.1%. Reported Q2 GAAP EPS of $0.70, and record adjusted EPS of $1.18.
SEC Form 6-K filed by Oatly Group AB SEC··Consumer StaplesSEC Form 6-K filed by Oatly Group AB
6-K - Oatly Group AB (0001843586) (Filer)
SEC Form 8-K filed by Genprex Inc. Extreme Networks Reports First Quarter Fiscal Year 2027 Financial Results PR··TelecommunicationsExtreme Networks Reports First Quarter Fiscal Year 2027 Financial Results
Revenue climbs 10% on seven straight quarters of double-digit growth Strong Extreme Platform ONETM Bookings help drive SaaS ARR growth up 22% Extreme Networks, Inc. ("Extreme") (NASDAQ:EXTR) today released financial results for its first quarter ended September 30, 2026. "Extreme delivered its seventh consecutive quarter of double-digit year-over-year growth in Q1. Demand for Extreme Platform ONE continues to accelerate, with strong quarter-over-quarter subscription gains. Platform ONE bookings are now over 50% of subscription bookings, up 5x from the prior year. Based on the strength of our business and visibility of demand for our solutions, we are confident in calling 10% growth ne
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International PR··Health CareMineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks - - New hormonal and urinary protein data show a 41.5% reduction in serum aldosterone with additional significant reductions in albuminuria and proteinuria -